Anthony S. Fiorino Net Worth

The estimated Net Worth of Anthony S. Fiorino is at least $75 dollars as of 22 May 2018. Anthony Fiorino owns over 25,000 units of Navidea Biopharmaceuticals Inc stock worth over $75 and over the last 10 years Anthony sold NAVB stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Anthony Fiorino NAVB stock SEC Form 4 insiders trading

Anthony has made over 5 trades of the Navidea Biopharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Anthony bought 25,000 units of NAVB stock worth $6,000 on 22 May 2018.

The largest trade Anthony's ever made was buying 50,000 units of Navidea Biopharmaceuticals Inc stock on 17 May 2018 worth over $13,000. On average, Anthony trades about 10,478 units every 150 days since 2014. As of 22 May 2018 Anthony still owns at least 75,000 units of Navidea Biopharmaceuticals Inc stock.

You can see the complete history of Anthony Fiorino stock trades at the bottom of the page.

What's Anthony Fiorino's mailing address?

Anthony's mailing address filed with the SEC is C/O BRAINSTORM CELL THERAPEUTICS INC., 605 THIRD AVENUE, 34TH FLOOR, NEW YORK, NY, 10158.

Insiders trading at Navidea Biopharmaceuticals Inc

Over the last 13 years, insiders at Navidea Biopharmaceuticals Inc have traded over $3,167,813 worth of Navidea Biopharmaceuticals Inc stock and bought 7,718,496 units worth $6,241,151 . The most active insiders traders include John K Jr. Scott, Perry A Karsen, and Life Sciences, Llc Platinum.... On average, Navidea Biopharmaceuticals Inc executives and independent directors trade stock every 63 days with the average trade being worth of $159. The most recent stock trade was executed by John K Jr. Scott on 10 April 2022, trading 3,260 units of NAVB stock currently worth $3.

What does Navidea Biopharmaceuticals Inc do?

navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de

Complete history of Anthony Fiorino stock trades at Brainstorm Cell Therapeutics and Navidea Biopharmaceuticals Inc

Navidea Biopharmaceuticals Inc executives and stock owners

Navidea Biopharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Jed Latkin,
  Chief Executive Officer, Chief Financial Officer, Chief Operating Officer
• Dr. Michael Stanley Rosol Ph.D.,
  Sr. VP & Chief Medical Officer
• Michael Rosol,
  Chief Medical Officer
• Y. Michael Rice,
  Independent Chairman of the Board
• S. Kathryn Rouan,
  Independent Director
• Adam Cutler,
  Independent Director
• Claudine Bruck,
  Independent Director
• Dr. Michel Mikhail Ph.D.,
  Chief Regulatory Officer
• Jeffrey Smith,
  VP of Operations
• Joel Harrison Kaufman,
  Chief Bus. Officer
• William J. Regan,
  Chief Strategy Officer & Chief Compliance Officer
• Erika Gibson,
  Director of Fin. & Admin.
• Alexander L Cappello,
  Director
• Anthony S. Fiorino,
  Director
• Mark I Greene,
  Director
• Brent L Larson,
  EVP, CFO, Treas and Secy
• Gordon A Troup,
  Director
• Eric K Rowinsky,
  Director
• Thomas J Klima,
  SVP & Chief Commercial Ofc
• William J. Regan,
  SVP-Global Regulatory Strategy
• Michael M Goldberg,
  Director
• Frederick O Cope,
  Senior VP and CSO
• John K Jr. Scott,
  
• Life Sciences, Llc Platinum...,
  
• Rodger A Brown,
  Vice President
• Perry A Karsen,
  Director
• Thomas H. Tulip,
  President
• Mark Platinum Management (N...,
  
• Brendan A Ford,
  Director
• Mark Jerome Pykett,
  Pres. & CEO
• Cornelia Reininger,
  SVP & Chief Medical Officer
• Jess Jones,
  Director
• Anton Gueth,
  Director
• Dana J Moss,
  
• Joel H. Kaufman,
  Chief Business Officer
• Malcolm G Witter,
  Director
• Amit Bhalla,
  Director
• Michel Mikhail,
  Chief Regulatory Officer
• Agnieszka Winkler,
  Director
• Thomas F Farb,
  Director
• Joshua M. Wilson,
  Director
• Jill Stefanelli,
  
• Craig Dais,
  CHIEF FINANCIAL OFFICER